JP2008500963A - 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたｈｉｖワクチン活性 - Google Patents
第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたｈｉｖワクチン活性 Download PDFInfo
- Publication number
- JP2008500963A JP2008500963A JP2007503063A JP2007503063A JP2008500963A JP 2008500963 A JP2008500963 A JP 2008500963A JP 2007503063 A JP2007503063 A JP 2007503063A JP 2007503063 A JP2007503063 A JP 2007503063A JP 2008500963 A JP2008500963 A JP 2008500963A
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- antigen
- immunogen
- immunomodulatory oligonucleotide
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 71
- 230000002519 immonomodulatory effect Effects 0.000 title claims abstract description 61
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract description 17
- 230000000694 effects Effects 0.000 title description 6
- 229940033330 HIV vaccine Drugs 0.000 title description 2
- 239000000427 antigen Substances 0.000 claims abstract description 87
- 108091007433 antigens Proteins 0.000 claims abstract description 87
- 102000036639 antigens Human genes 0.000 claims abstract description 87
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 77
- 208000030507 AIDS Diseases 0.000 claims abstract description 11
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 7
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 7
- 230000002163 immunogen Effects 0.000 claims description 65
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 22
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical group C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 208000010648 susceptibility to HIV infection Diseases 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 102100037850 Interferon gamma Human genes 0.000 description 21
- 108010074328 Interferon-gamma Proteins 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 13
- 102000003814 Interleukin-10 Human genes 0.000 description 12
- 108090000174 Interleukin-10 Proteins 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 210000004988 splenocyte Anatomy 0.000 description 8
- 102000001327 Chemokine CCL5 Human genes 0.000 description 7
- 108010055166 Chemokine CCL5 Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 7
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 238000001308 synthesis method Methods 0.000 description 7
- 238000004945 emulsification Methods 0.000 description 6
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 238000011510 Elispot assay Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- -1 phosphothioate nucleoside Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108700012434 CCL3 Proteins 0.000 description 2
- 102000000013 Chemokine CCL3 Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 description 2
- 101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 description 2
- 101000648491 Homo sapiens Transportin-1 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100028748 Transportin-1 Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 102000018568 alpha-Defensin Human genes 0.000 description 2
- 108050007802 alpha-defensin Proteins 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 101000599778 Homo sapiens Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 description 1
- 101000988591 Homo sapiens Minor histocompatibility antigen H13 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 102100029083 Minor histocompatibility antigen H13 Human genes 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000023385 chemokine (C-C motif) ligand 5 production Effects 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55287104P | 2004-03-12 | 2004-03-12 | |
| PCT/US2005/008238 WO2005089231A2 (en) | 2004-03-12 | 2005-03-11 | Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008500963A true JP2008500963A (ja) | 2008-01-17 |
| JP2008500963A5 JP2008500963A5 (enExample) | 2008-05-15 |
Family
ID=34994209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503063A Pending JP2008500963A (ja) | 2004-03-12 | 2005-03-11 | 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたｈｉｖワクチン活性 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050266015A1 (enExample) |
| EP (1) | EP1729802A4 (enExample) |
| JP (1) | JP2008500963A (enExample) |
| CN (1) | CN101217973A (enExample) |
| AU (1) | AU2005222909B2 (enExample) |
| CA (1) | CA2557443A1 (enExample) |
| WO (1) | WO2005089231A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| CN1753687A (zh) | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| KR101251707B1 (ko) | 2006-09-27 | 2013-04-11 | 콜리 파마슈티칼 게엠베하 | 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체 |
| BR112012030337B1 (pt) * | 2010-05-28 | 2021-04-27 | Coley Pharmaceutical Group, Inc | Vacina compreendendo um ou mais oligonucleotídeo(s) de cpg isolado(s) ou um agonista de tlr e colesterol, e uso da mesma |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5912332A (en) * | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
| KR101123489B1 (ko) * | 2003-01-16 | 2012-03-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 개질된 면역자극성 디뉴클레오티드를 이용한 올리고뉴클레오티드-기재 화합물의 면역자극 특성의 조절 |
| CN101291691A (zh) * | 2003-08-28 | 2008-10-22 | 免疫反应公司 | 免疫原性hiv组合物和相关方法 |
-
2005
- 2005-03-11 AU AU2005222909A patent/AU2005222909B2/en not_active Ceased
- 2005-03-11 JP JP2007503063A patent/JP2008500963A/ja active Pending
- 2005-03-11 CA CA002557443A patent/CA2557443A1/en not_active Abandoned
- 2005-03-11 WO PCT/US2005/008238 patent/WO2005089231A2/en not_active Ceased
- 2005-03-11 CN CNA2005800079845A patent/CN101217973A/zh active Pending
- 2005-03-11 US US11/078,654 patent/US20050266015A1/en not_active Abandoned
- 2005-03-11 EP EP05725427A patent/EP1729802A4/en not_active Withdrawn
Non-Patent Citations (4)
| Title |
|---|
| JPN6010068912, "Ｉｍｍｕｎｅ Ｒｅｓｐｏｎｓｅ Ｌｉｃｅｎｓｅｓ Ｈｙｂｒｉｄｏｎ’ｓ ＡＭＰＬＩＶＡＸ ｖａｃｃｉｎｅ ａｄｊｕｖａｎｔ", ＢＩＯＴＥＣＨ Ｐａｔｅｎｔ Ｎｅｗｓ, 200310, Ｖｏｌ．１７， Ｎｏ．１０, ｐ．１４−１５ * |
| JPN6010068913, ＫＡＮＤＩＭＡＬＬＡ， Ｅ．Ｒ．， ｅｔ ａｌ．, "Ｄｉｖｅｒｇｅｎｔ ｓｙｎｔｈｅｔｉｃ ｎｕｃｌｅｏｔｉｄｅ ｍｏｔｉｆ ｒｅｃｏｇｎｉｔｉｏｎ ｐａｔｔｅｒｎ： ｄｅｓｉｇｎ ａｎｄ ｄｅｖｅｌｏｐｍｅｎｔ ｏｆ ｐｏｔｅｎｔ ｉｍｍｕｎｏｍｏｄ", Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓｅａｒｃｈ, 2003, Ｖｏｌ．３１， Ｎｏ．９, ｐ．２３９３−２４００ * |
| JPN6010068914, ＨＯＲＮＥＲ， Ａ．Ａ．， ｅｔ ａｌ．, "Ｉｍｍｕｎｏｓｔｉｍｕｌａｔｏｒｙ ＤＮＡ−Ｂａｓｅｄ Ｖａｃｃｉｎｅｓ Ｅｌｉｃｉｔ Ｍｕｌｔｉｆａｃｅｔｅｄ Ｉｍｍｕｎｅ Ｒｅｓｐｏｎｓｅｓ Ａｇａｉｎｓｔ ＨＩＶ ａｔ Ｓｙｓｔｅｍｉｃ ａｎ", Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｙ, 2001, Ｖｏｌ．１６７, ｐ．１５８４−１５９１ * |
| JPN6010068915, ＬＩＭＳＵＷＡＮ， Ａ．， ｅｔ ａｌ．, "Ｓａｆｅｔｙ ａｎｄ ｉｍｍｕｎｏｇｅｎｉｃｉｔｙ ｏｆ ＲＥＭＵＮＥ ＴＭ ｉｎ ＨＩＶ−ｉｎｆｅｃｔｅｄ Ｔｈａｉ ｓｕｂｊｅｃｔｓ", Ｖａｃｃｉｎｅ, 1998, Ｖｏｌ．１６， Ｎｏ．２／３, ｐ．１４２−１４９ * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050266015A1 (en) | 2005-12-01 |
| EP1729802A4 (en) | 2009-12-16 |
| CA2557443A1 (en) | 2005-09-29 |
| AU2005222909B2 (en) | 2010-03-11 |
| WO2005089231A3 (en) | 2007-12-06 |
| WO2005089231A2 (en) | 2005-09-29 |
| CN101217973A (zh) | 2008-07-09 |
| AU2005222909A1 (en) | 2005-09-29 |
| EP1729802A2 (en) | 2006-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2372960C (en) | Hiv immunogenic compositions and methods | |
| US6737066B1 (en) | HIV immunogenic compositions and methods | |
| Sjölander et al. | Immune responses to ISCOM® formulations in animal and primate models | |
| Courtney et al. | Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens | |
| US20080199494A1 (en) | Vaccine | |
| Otero et al. | Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model | |
| Borsutzky et al. | Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant | |
| KR100622716B1 (ko) | 인터루킨-12 및 허피스 심플렉스 바이러스 항원을포함하는 백신 | |
| JP2012006949A (ja) | アジュバント混合製剤 | |
| Becker et al. | The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant | |
| JP2008500963A (ja) | 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたｈｉｖワクチン活性 | |
| Huang et al. | Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses | |
| US20070253979A1 (en) | Immunogenic Hiv Compositions and Related Methods | |
| US20030044428A1 (en) | Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment | |
| O'Hagan et al. | Novel adjuvants and delivery systems for HIV vaccines | |
| HK1114789A (en) | Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide | |
| WO2024173143A2 (en) | Vaccines incorporating hiv th/ctl epitope peptides to prevent and treat patients with hiv infection and aids | |
| KR20070019635A (ko) | 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법 | |
| MX2008006488A (es) | Nuevos adyuvantes con base en conjugados de bisaciloxipropilcisteina y derivados y sus usos en composiciones farmaceuticas | |
| Poonam | Induction of strong cellular immune responses in the gut mucosa against HIV-1 using a combination vaccine of recombinant Clostridium perfringens and HIV-1 virus like particles | |
| ZA200108559B (en) | HIV immunogenic compositions and methods. | |
| MXPA01010784A (en) | Hiv immunogenic compositions and methods | |
| SA02230071B1 (ar) | تركيبات مولدة للمضاد ومساعدة تشمل فوسفات جلوكوز أمين أمينوالكيل و -il-12 أو csf gm- |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101214 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110712 |